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Selective Inhibition of p300 HAT Blocks Cell Cycle
Progression, Induces Cellular Senescence, and Inhibits
the DNA Damage Response in Melanoma Cells
Gai Yan1, Mark S. Eller2,4, Courtney Elm2, Cecilia A. Larocca1, Byungwoo Ryu2, Izabela P. Panova2,
Beverley M. Dancy3, Erin M. Bowers3, David Meyers3, Lisa Lareau1, Philip A. Cole3, Sean D. Taverna3 and
Rhoda M. Alani1,2,3
Epigenetic events, including covalent post-translational modifications of histones, have been demonstrated to
have critical roles in tumor development and progression. The transcriptional coactivator p300/CBP possesses
both histone acetyltransferase (HAT) activity and scaffolding properties that directly influence the transcriptional
activation of targeted genes. We have used a potent and specific inhibitor of p300/CBP HAT activity, C646, in order
to evaluate the functional contributions of p300/CBP HAT to tumor development and progression. Here we report
that C646 inhibits the growth of human melanoma and other tumor cells and promotes cellular senescence.
Global assessment of the p300 HAT transcriptome in human melanoma identified functional roles in promoting
cell cycle progression, chromatin assembly, and activation of DNA repair pathways through direct transcriptional
regulatory mechanisms. In addition, C646 is shown to promote sensitivity to DNA damaging agents, leading to
the enhanced apoptosis of melanoma cells after combination treatment with cisplatin. Together, our data suggest
that p300 HAT activity mediates critical growth regulatory pathways in tumor cells and may serve as a potential
therapeutic target for melanoma and other malignancies by promoting cellular responses to DNA damaging
agents that are currently ineffective against specific cancers.
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INTRODUCTION
Recent discoveries have allowed for the development of novel
therapies targeting epigenetic pathways in cancers including
DNA methyltransferases and histone deacetylases (Kelly et al.,
2010). Biochemical and genetic data demonstrate complex
roles of histone acetyltransferases (HATs) in determining cell
fate in both normal and diseased tissues, making them a new
class of potential therapeutic targets (Dekker and Haisma,
2009). The KAT3 family HAT protein p300/CBP has over 400
binding partners and at least 75 substrates (Ogryzko et al.,
1996; Bedford et al., 2010). It acts as a transcriptional
coactivator and a scaffold protein, and its importance to
cell fate is reflected by its involvement in the regulation of
cell cycle, DNA synthesis, cellular differentiation, and organ
development (Chan and La Thangue, 2001). P300 has a
complex role in carcinogenesis. Missense mutations and
truncations of p300 have been found in solid tumors and
B-cell lymphoma, suggesting that it acts as a tumor suppressor
(Iyer et al., 2004; Pasqualucci et al., 2011). In contrast, p300 is
a transcriptional coactivator of known oncogenes, such as
c-jun and c-fos. Furthermore, in rare cases, a fusion between
the MYST family HAT protein MOZ and p300 is thought
to contribute to leukemia development (Chan and La
Thangue, 2001; Katsumoto et al., 2008). In HCT116 colon
cancer cells, p300 prevents premature G1/S transitions by
inhibiting RB phosphorylation, whereas p300-null cells
become sensitive to UV damage and undergo apoptosis (Iyer
et al., 2004, 2007).
Although mutations of p300 have not been identified in
human melanoma, strong evidence has linked p300 to
melanoma development. A genome-wide SAM (significant
analysis of microarray) analysis has shown that the EP300
gene is upregulated in melanoma cell lines (Lin et al., 2008).
In addition, p300 regulates the melanocyte lineage–specific
MITF transcription factor, which is amplified in metastatic
melanomas and is associated with antiapoptotic and angio-
genic activities (Sato et al., 1997; Garraway et al., 2005;
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Yajima et al., 2011). Normal human melanocytes undergo
growth arrest, cyclin E repression, and activation of cellular
senescence following p300 HAT inhibition via a bisubstrate
analog, Lys-CoA, or a dominant negative p300 transgene. This
transgene was also shown to induce cellular senescence in
melanomas (Bandyopadhyay et al., 2002).
Inhibitors of p300 HAT function have been derived from
natural compounds that largely lack specificity (Dekker and
Haisma, 2009), whereas bisubstrate analogs such as Lys-CoA
are more selective but have limited use in biological studies.
On the basis of the recently elucidated structure of the p300
HAT domain, a virtual ligand screen identified a potent and
selective inhibitor of p300 HAT activity known as C646 (Liu
et al., 2008; Bowers et al., 2010). We have demonstrated the
specificity of C646 both in vitro and in culture (Bowers et al.,
2010; Crump et al., 2011), and it has been used to assess p300
HAT functions in prostate cancer and leukemia (Santer et al.,
2011; Wang et al., 2011). Here we evaluate the functional
significance of p300 HAT activity in human melanoma and
explore the global p300 HAT transcriptome using C646. We
find significant effects of C646 on tumor cell growth, cellular
senescence, and the DNA damage response, which are media-
ted by direct transcriptional effects on target genes. In addition,
C646 sensitizes melanoma cells to DNA damaging agents,
suggesting potential utility as a therapeutic target for this disease.
RESULTS
Blockade of p300 HAT activity inhibits tumor cell growth
Previous data from our group and others have suggested that
p300 HAT is important for tumor cell growth (Bowers et al.,
2010). To evaluate the specific functional significance of p300
HAT in human melanomas, we explored the effect of p300
HAT blockade on melanoma cell proliferation using the
selective inhibitor C646 in a 3H-thymidine incorporation
assay. 3H-thymidine assay results were further validated
using an XTT assay (Supplementary Figure S3 online), recog-
nizing the limitations associated with tetrazolium salt–based
cell viability assays (Scudiero et al., 1988; Wang et al., 2010).
Ten cell lines representing radial, vertical, and metastatic
phases of melanoma progression were evaluated, with the
majority demonstrating significant growth inhibition following
treatment with C646 (Figure 1a) versus the nonfunctional
control compound C37 (Bowers et al., 2010). Furthermore, the
degree of growth inhibition by C646 was not associated with
tumor stage or B-raf status. It is noteworthy that previous
studies from our group failed to demonstrate significant
differences in EP300 transcript levels between our
melanoma lines and normal melanocytes (Ryu et al., 2007).
To explore the broad spectrum of the growth inhibitory
effects of C646 in cancer, we submitted C646 to the NCI
Developmental Therapeutics Program NCI-60 screen (http://
dip.nci.nih.gov/index.html) (Shoemaker, 2006). The data from
the screen indicated that C646 inhibited proliferation of
multiple cancers with IC50 values in the low micromolar
range (Figure 1c, Supplementary Figure S1, S2 online). Several
tumor cell lineages were particularly sensitive to C646,
suggesting that p300 HAT activity may be more broadly
important for cellular proliferation in these tumor types.
p300 HAT inhibition blocks S-phase progression in melanoma
cells
Preliminary work from our group suggested that C646 induces
a G1 cell cycle arrest in melanoma cells (Bowers et al., 2010).
To more thoroughly assess the cell cycle effects of C646,
melanoma lines from varying stages of progression were
evaluated. We observed a statistically significant, dose-
dependent decrease in %S-phase cells in C646-sensitive cell
lines (Figure 1b, Supplementary Figure S4 online). In contrast,
minimal effects on S-phase progression were seen in the
C646-resistant 1205Lu cells (Figure 1b, Supplementary
Figure S4 online).
p300 regulates genes involved in cell cycle regulation and DNA
repair
To evaluate the transcriptional significance of p300 HAT
activity in mediating melanoma growth, we performed com-
prehensive gene expression profiling of the C646-sensitive cell
line, WM35, following 6 and 24 hours of C646 treatment.
These treatment time points were chosen on the basis of
previous data demonstrating significant effects on histone
acetylation within hours after C646 treatment and the asso-
ciated onset of cell cycle arrest at 24 hours post treatment
(Bowers et al., 2010). We found few differences in the
expression profiles between the C646- and DMSO-treated
cells following 6 hours of treatment; however, we observed
significant alterations in gene expression between the two
treatment groups at 24 hours of treatment, with 416 genes
downregulated and 199 genes upregulated by more than
2-fold in C646-treated cells (Supplementary Figure S5a online).
We then performed functional annotation of genes altered by
more than 2-fold in the 24-hour sample according to biolo-
gical processes and molecular functions. Although the upre-
gulated genes could not be classified into any gene ontology
categories with high significance (Supplementary Figure S5b
online), among the downregulated genes we observed statis-
tically significant representation of genes involved in cell cycle
regulation, cell division, and chromatin-associated functions
such as nucleosome assembly, chromosome segregation, and
DNA damage checkpoint control. It is noteworthy that many
of these genes also possess chromatin/DNA-binding functions
(Figure 2a).
Microarray results on selected genes of interest were
validated using quantitative real-time PCR (qPCR) on biologi-
cal replicates of the array samples (Figure 2b, Table 1).
Interestingly, the vast majority of genes whose expression
was altered by C646 treatment of WM35 cells failed to be
altered in the C646-insensitive 1205Lu cells, suggesting a
specific correlation of the expression profile with the tumor
cell growth response (Figure 2b).
Inhibition of p300 HAT activity affects histone acetylation but
not p300 localization at targeted gene promoters
Acetylation of promoter histones is associated with a tran-
scriptionally permissive chromatin structure. To determine the
mechanisms underlying p300 HAT-regulated gene expression,
we first evaluated whether p300 HAT inhibition directly
affects transcription by interfering with histone acetylation
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near gene promoters. We performed a chromatin immuno-
precipitation (ChIP) assay followed by qPCR analysis of
acetylated histone H3 enrichment at the promoter regions of
selected DNA repair and cell cycle regulatory genes that were
identified in our microarray analyses. Notably, the genes that
were repressed after C646 treatment were also depleted in
acetylated H3 at the promoters (Figure 2c). TP53 expression
was upregulated after C646 treatment; however, there was no
increase in H3 acetylation at the tested sequence (Figure 2c).
In contrast, we did not observe changes in p300 enrichment
at the promoter sites of interest following C646 treatment,
except for an increase seen at the RPA2 gene (Figure 2c),
suggesting that specific inhibition of p300 HAT activity does
not interfere with p300–chromatin interactions; rather, such
an inhibition targets the localization of acetylated histones to
promoter sites. These findings are consistent with recent data
that also found no alterations in p300 enrichment at c-fos and
c-jun loci following its inhibition in vivo (Crump et al., 2011).
p300 HAT inhibition activates G1/S cell cycle arrest mechanism
Given the results from our microarray study, we sought to
further evaluate the effect of p300 HAT inhibition on cell
cycle regulatory protein expression in the melanoma cell
lines. We found that cyclins A2 (CCNA2) and E2 (CCNE2)
were among the most downregulated genes after 24 hours of
C646 treatment of WM35 cells (Table 1). Remarkably, we also
observed a dose-dependent decrease in the protein levels of
cyclins A and E in these cells (Figure 3a). Furthermore, this
decrease was accompanied by an increased expression of p53
and its downstream effector p21, a known inhibitor of cyclin-
dependent kinases (Figure 3a). No changes were noted in the
level of cyclin D1, which is known to be overexpressed rather
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Figure 1. Effect of p300 HAT inhibition on cancer cell proliferation. (a) 3H-thymidine uptake in melanoma cells treated for 24 hours with 10mM C646, 10mM C37,
or 0.1% DMSO. Boxed: B-raf wild-type; unboxed: B-raf(V600E). The data are normalized to DMSO. N¼ 3; error bars: SD. (b) Cell cycle profiles of WM35,
WM983B, and 1205Lu after 24 hours of treatment. Right panel: %S phase normalized to DMSO. N¼ 3. P-values were calculated from Student’s t-test.
Representative histograms are shown in Supplementary Figure S3. (c) Data from the one-dose NCI-60 screen. Bars indicate growth percent (of each cell line)—
mean growth percent (of all cell lines); smaller numbers correspond to greater growth inhibition. See Supplementary Figure S1, S2 online for details.
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than repressed in senescent cells (Meyyappan et al., 1998;
Han et al., 1999; Burton et al., 2007), nor were there any
changes in the levels of B-raf, Bcl-2, PARP, or PCNA
(Supplementary Figure S6 online). Interestingly, in WM983B
cells, in which the TP53 gene is mutated (Weiss et al., 1994),
C646 continued to induce cell cycle arrest (Figure 1b)
characterized by cyclin A repression and p21 activation
(Figure 3a), suggesting a p53-independent mechanism for
growth arrest in these cells. In contrast to the responsive cells,
the C646-resistant cell line 1205Lu showed minimal effects on
cyclin A expression following C646 treatment; however, p53
and p21 were both upregulated to a similar extent as seen in
the WM35 cells (Figure 3a), suggesting the existence of a
bypass mechanism preventing p21-associated growth arrest.
Notably, the mRNA level of CCNA2 decreased dose depen-
dently in C646-treated WM35 cells; however, such effects
were significantly reduced in 1205Lu cells (Figure 3b), sug-
gesting that the extent of cyclin A attenuation in these cells
may not be sufficient for cell cycle arrest. The involvement of
cyclin A in melanoma cell cycle regulation was further
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Figure 2. Gene expression profiling of WM35 cells after p300 HAT inhibition. (a) Gene ontology (GO) analysis of genes that were repressed by X2-fold
after 24 hours of treatment with 20mM C646. The P-values represent the significance of the gene clustering. (b) qPCR validation of selected gene targets in WM35
and 1205Lu cells. The data were normalized to the DMSO control with GAPDH as the endogenous gene control. NX3. (c) Chromatin immunoprecipitation
assay followed by qPCR (ChIP-qPCR) analysis of acetylated H3 and p300 enrichment near the transcription start sites of selected genes. The data were normalized
to total H3 ChIP; a GAPDH promoter sequence served as the endogenous control. NX3.
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demonstrated with the small interfering RNA knockdown of
CCNA2 mRNA, which also resulted in decreased proliferation
of the C646-responsive WM35 cells (Figure 3c and d).
On the basis of the NCI-60 screening results and our previous
data (Bowers et al., 2010), we examined cyclin A expression in
lung and glioblastoma cancer lines to determine whether the
growth inhibitory effects in these tumor cell lineages were also
associated with altered cell cycle protein expression. Indeed,
both the transcript and protein levels of cyclin A were
decreased to various extents in these cancers after 24 hours of
C646 treatment, suggesting that p300 HAT activity has similar
functional roles in regulating cell cycle progression in these
tumors (Supplementary Figure S7, S8 online).
Prolonged p300 HAT inhibition promotes cellular senescence
To determine the functional consequences of extended p300
HAT inhibition on melanoma cellular phenotypes, we eval-
uated cellular apoptosis after 3 and 5 days of treatment in
WM35 cells and observed no statistically significant differ-
ences in the percentages of apoptotic populations between
the C646-treated and DMSO-treated cells at either time
point (P40.05) (Figure 4a). We further sought to define
the specific effects of C646 treatment on cellular
senescence pathways by evaluating C646-treated cells
for senescence-activated beta-galactosidase activity and
senescence-associated heterochromatin foci formation. We
found that extended C646 treatment of multiple responsive
cell lines led to increased cellular senescence versus the
DMSO control (Figure 4b and c), suggesting that p300 HAT
inhibition had a cytostatic rather than an apoptotic effect on
melanoma cells leading to senescence-associated growth
arrest. This effect was not observed in the nonresponsive
1205Lu cells (Figure 4b).
p300 regulates the DNA damage response in melanoma cells
As our microarray data demonstrated the repression of DNA
repair genes following p300 HAT inhibition (Table 1), we
sought to explore the functional role of p300 HAT activity in
the DNA damage response. The phosphorylation of the
histone variant H2AX (gH2AX) occurs after DNA double-
strand breaks and helps recruit repair proteins to the site of
damage (Lukas et al., 2011). In cells treated with C646 for
24 hours, we observed a decreased level of gH2AX protein,
suggesting that tumor cells may not be able to efficiently
recognize DNA damage following p300 HAT inhibition
(Figure 5a).
To determine how cells responded to induced DNA damage
in the presence of a HAT inhibitor, we evaluated the responses
of melanoma cells to a combination treatment of C646 and
cisplatin. As our expression profiling studies demonstrated a
loss of DNA damage response gene expression after HAT
inhibition, we anticipated that DNA damaging agents would
allow for enhanced apoptotic responses in the presence
of a potent, selective HAT inhibitor. Interestingly, 24-hour
Table 1. PCR-validated gene targets of p300 HAT
Gene
Fold
change
Known function(s)
Repressed
Family with sequence similarity 111, member B FAM111B  42.5 —
Histone cluster 1, H2bb HIST1H2BB  29.1 Chromatin assembly
Ubiquitin-like with PHD and ring finger domains 1 UHRF1  14.5 G1/S transition, p53-dependent DNA damage checkpoint
Cyclin E2 CCNE2  12.7 G1/S transition
DEP domain containing 1 DEPDC1  12.4 Inhibition of apoptosis
X-ray repair complementing defective repair in
Chinese hamster cells 2
XRCC2  11.3 Homologous recombination
Cyclin A2 CCNA2 7.2 G1/S and G2/M transition
RAD51 homolog RAD51 5.6 Homologous recombination
Bloom syndrome, RecQ helicase-like BLM 5.3 30–50 Helicase activity, suppression of inappropriate recombination
Breast cancer 2, early onset BRCA2 4.2 Homologous recombination
Replication protein A2 RPA2 2.6 Homologous recombination
Overexpressed
Protease, serine, 35 PRSS35 5.7 —
Tripartite motif containing 38 TRIM38 4.3 —
microRNA 34a MIR34A 2.6 —
Tissue inhibitor of metalloproteinase 3 TIMP3 2.4 Irreversible inactivation of metalloproteinases
Tumor protein p53 TP53 1.2 Response to diverse cellular stresses, promotion of cell cycle arrest, apoptosis,
senescence, and DNA repair
Abbreviation: HAT, histone acetyltransferase.
The numbers indicate the relative expression level fold change in cells treated with C646 for 24 hours over the DMSO control. Descriptions of gene functions
are taken from PubMed gene search. ‘‘—‘‘ Indicates that no broad cellular function has been associated with a particular gene.
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pretreatment of melanoma cells with 10mM C646 followed by
cisplatin led to increased apoptosis in WM35 cells compared
with cisplatin treatment alone; however, a 20-mM C646
pretreatment led to a reduction in apoptotic cells after
cisplatin treatment (Figure 5b). Given that cisplatin efficacy
is dependent on cycling cells, it is possible that the 20-mM
C646-treated cells were more likely to be growth arrested than
those treated at 10mM, thereby rendering the cisplatin less
effective. We conclude that p300 HAT inhibition may sensi-
tize cancer cells to DNA damaging agents within an appro-
priate context.
DISCUSSION
Epigenetic alterations in cancers have been identified as a
hallmark of the malignant phenotype; however, the functional
significance of particular epigenetic signatures in cancer has
not been fully realized. Although previous studies have sought
to identify global p300 target genes and pathways, such work
is unable to specifically distinguish molecular targets of p300
HAT function versus targets associated with the transcriptional
adaptor function of p300. Here, we use a specific inhibitor of
p300 HAT, C646, as a tool to evaluate target genes specifi-
cally associated with the HAT activity of p300. Although we
previously reported the selectivity of C646 against p300
(Bowers et al., 2010), we now further demonstrate that the
cellular consequences of C646 treatment are specifically
linked to the loss of p300 HAT function. Our cyclin
expression and senescence data are consistent with previous
findings of p300 function in melanocytes. In addition, the
overall pattern of gene expression changes in C646-treated
cells, which is highly skewed toward gene repression versus
activation, also strongly supports targeted transcriptional
effects resulting from the loss of HAT activity. Furthermore,
identification of specific S-phase repression in melanoma cells
and specific repression of S-phase histone HIST1H2BB
(Table 1) is consistent with previous findings demonstrating
the regulation of S-phase histone transcription by p300 (He
et al., 2011).
Repression of cyclin A in growth-arrested melanoma cells
after p300 HAT inhibition has not been previously reported;
however, as the role of cyclin A in promoting G1/S and G2/M
transition has previously been well established (Celis et al.,
1984; Pagano et al., 1992; Shapiro and Harper, 1999), this
finding is not surprising. It is notable that the degree of cyclin
A repression observed is highly correlated with tumor cell
responsiveness to C646, suggesting that cyclin A may serve as
a useful marker for clinical response to p300 inhibition.
The microarray analysis of p300 HAT-associated transcripts
and the accompanying ChIP data suggest that p300 regulates
targeted gene expression through a direct transcriptional
mechanism. The reduced acetylation of histones associated
with C646 treatment is likely to antagonize the chromatin
remodeling needed for initiation and elongation by RNA Pol
II; however, we cannot exclude the possibility that direct
inhibition of p300-mediated acetylation of transcription
factors and coactivators by C646 may indirectly lead to
subsequent inhibition of transcription. Such complexity could
also account for the observed upregulation of a small set
of transcripts following p300 HAT inhibition. Alternatively,
such outcomes may be associated with downstream effects of
direct transcriptional targets of p300 HAT.
Our previous gene expression profile study identified a set
of molecular characteristics that distinguish aggressive mela-
noma phenotypes from less aggressive ones (Ryu et al., 2007).
Such molecular characteristics of aggressive melanomas
included the following: upregulation of activators of cell
cycle progression, DNA replication, and repair; loss of
genes associated with cellular adhesion and melanocyte
differentiation; and upregulation of genes associated with
apoptosis resistance. The two classes of upregulated genes
are, notably, also found to be significantly repressed following
p300 inhibition in the current study (Supplementary Table S3
online), suggesting that blocking of p300 HAT activity may
reduce the metastatic potential of melanoma cells as an
alternative therapeutic approach.
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NX3. Please note that the western blot antibody detects both CCNA1 and
CCNA2, whereas the qPCR only detects CCNA2. (c) Relative expression of
CCNA2 after small interfering RNA (siRNA) transfection, as determined by
qRT–PCR. (d) Relative cell proliferation measured by the MTT assay 96 hours
after plating the siRNA-transfected cells.
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One of the major obstacles in treating melanoma versus
other malignancies is its resistance to DNA damage. The
correlation between DNA repair gene overexpression and
cancer malignancy, as determined by other studies
(Winnepenninckx et al., 2006; Kee and D’Andrea, 2010; Kao
et al., 2011), coupled to our finding that inhibition of p300
HAT activity results in the repression of DNA repair genes,
suggests that p300 contributes to melanoma survival at least in
part through the maintenance of genomic stability. Although
C646-induced growth arrest was found to hinder cisplatin
activity at high concentrations of C646 in our study, it is yet to
be studied how p300 inhibition affects the cellular response to
other chemotherapeutic agents or ionizing radiation. On the
basis of our current data, we suggest that future work focus on
the elucidation of the detailed mechanisms of p300-regulated
pathways in targeted cancers and the potential role for p300
HAT inhibition as a therapeutic strategy targeting epigenetic
changes in susceptible malignancies.
MATERIALS AND METHODS
Detailed information on cell culture and experimental methods is
provided in the Supplementary Material online.
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Figure 4. Analyses of WM35 cell phenotype after extended p300 inhibition. (a) FACS analysis of apoptotic cells after 3 and 5 days of treatment with C646 (20mM)
or DMSO. The population in the lower right quadrant contains early apoptotic cells. The numbers represent the average % of apoptotic cells from three
independent experiments±SD. P-values were derived from Student’s t-test. (b) Representative images of senescence-activated beta-galactosidase (SA-b-gal)
staining in WM35, WM902B, A375, and 1205Lu cells treated for 4 d. Strong perinuclear staining is considered SA-b-gal positive. Bar¼ 100mm. (c) Promyelocytic
leukemia protein (PML) immunofluorescence staining for senescence detection of WM35 and WM902B cells. C646 treatment induced larger and flattened
nucleoli, as well as more senescence-associated heterochromatin foci (SAHF) formations compared with the DMSO treatment. It is noteworthy that DMSO-treated
cells also showed basal levels of SAHF formation. Bar¼ 10mm.
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Cell treatment with compounds
To treat cells, C646 and C37 were dissolved in anhydrous DMSO to
10 mM and added to culture medium to the desired concentration. An
equal amount of DMSO was used as the vehicle control.
3H-thymidine incorporation
The use of thymidine incorporation to measure cell proliferation has
been extensively described previously (Shevach, 2001). 3H-thymidine
was added to cells in 96-well plates at 10mCi ml 1 for 5 hours and
cells were collected onto a filter mat using a cell harvester
(PerkinElmer, Waltham, MA). The radioactivity was measured with
a MicroBeta plate reader (PerkinElmer). The samples were tested in
triplicate. The data were normalized to the DMSO control.
NCI-60 screen
Detailed methodology of the screen is described at the NCI website
(http://dtp.nci.nih.gov/index.html) (Shoemaker, 2006). The initial one-
dose screen used 100mM of C646. The second stage was a 5-dose
screen using 0.01–100mM C646.
Cell cycle analysis
Cells were stained with propidium iodide according to a published
protocol (Darzynkiewicz et al., 2001). Data acquisition and analysis
were performed on an FACSCalibur flow cytometer with the
CellQuest software (BD Biosciences, San Jose, CA).
Microarray study
RNA was purified from C646- or DMSO-treated cells using the
Qiagen RNAeasy Kit and submitted to the microarray core facility at
JHMI for analysis on the Affymetrix GeneChip Human Exon 1.0 ST
Array. The data normalization and processing were performed by the
core facility. The gene ontology analysis was performed with Spotfire
(TIBCO, Somerville, MA).
qPCR
Complementary DNA was synthesized using the Superscript First
Strand Synthesis System (Invitrogen, Grand Island, NY). qPCR was
performed using the Power SYBR Green PCR Master Mix (ABI/
Invitrogen) as described in the Supplement. The primers were
designed using the NCBI PrimerBlast tool (Supplementary Table S1
online). Gene expression values were determined with the DDCt
method.
ChIP assay followed by qPCR
ChIP was performed based on a published protocol (O’Geen et al.,
2010). The antibodies included acetylated H3 (Millipore, Billerica,
MA, no. 06-599), total H3 (Abcam, Cambridge, MA, no. ab1791),
and p300 (Santa Cruz Biotechnology (SCBT), Dallas, TX, no. sc-585).
Primers for qPCR were designed to amplify a region near transcription
start (Supplementary Table S2 online). qPCR was performed using
SYBR Green.
Western blot
Whole-cell lysate was prepared as described in the supplement.
Western blots were performed as previously described (Cummings
et al., 2008). Antibodies were obtained from the following sources:
cyclin A (no. sc-596), cyclin D1 (no. sc-20044), PCNA (no. sc-56),
B-raf (no. sc-166), PARP (no. sc-7150), and b-actin (no. sc-1616-R)
were from SCBT; cyclin E2 (no. 4132) and p21 (no. 2946) were from
Cell Signaling Technology (Danvers, MA); p53 (no. OP43) was from
Calbiochem (Billerica, MA). The HRP-tagged secondary antibodies
were from Amersham (Pittsburgh, PA).
For the analysis of gH2AX, histones were extracted based on an
established protocol with modifications as described in the supple-
ment (Shechter et al., 2007). The antibody against gH2AX was from
Abcam (no. ab2893). Total H2AX (Millipore no. 07-627) was the
loading control.
Cyclin A knockdown
The CCNA2 small interfering RNAs (no. A-003205-19-0005 and
A-003205-21-0005) and the scrambled control (ON-TARGETplus
Non-targeting small interfering RNA no. 1, no. D-001810-01) were
ordered from Dharmacon (Thermo Scientific, Waltham, MA). The
protocols for the knockdown and the subsequent analysis of cell
proliferation are described in the supplement.
Apoptosis assay
Apoptosis was assessed with the Alexa Fluor 488 annexin V/propi-
dium iodide kit (Invitrogen no. V13241) according to the manufac-
turer’s protocol. Approximately 105 cells per sample were analyzed
by FACS.
For apoptosis analysis after C646/cisplatin co-treatment, the APO-
BrdU TUNEL Assay Kit (Invitrogen no. A35125) was applied to
paraformaldehyde-fixed cells according to the instructions. After
staining, the cells were incubated with the propidium iodide/RNase
solution from the kit for 30 minutes before FACS analysis.
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Figure 5. DNA damage response after p300 histone acetyltransferase (HAT)
inhibition. (a) Western blot of gH2AX in WM35 cells after 24 hours of C646
treatment. (b) FACS analysis of TUNEL-stained cells after combination
treatment with C646 and cisplatin. þ / : Presence/absence of a compound.
N¼ 3.
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Senescence detection
Senescent cells were detected by staining for lysosomal senescence-
activated beta-galactosidase activity with a commercial kit (Cell
Signaling no. 9860) and by immunofluorescent staining of promye-
locytic leukemia protein nuclear bodies using an established protocol
(Vernier et al., 2011).
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